Akebia Therapeutics (AKBA) Return on Capital Employed (2014 - 2026)

Akebia Therapeutics (AKBA) has 13 years of Return on Capital Employed data on file, last reported at 2.7% in Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 1535.0% year-over-year to 2.7% in Q1 2026; TTM through Mar 2026 was 2.7%, a 1535.0% increase from a year earlier, with the FY2025 full-year figure at 17.32%, up 5091.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 2.7%, down from 11.33% in the prior quarter.
• Over the last five years, Return on Capital Employed for AKBA reached as high as 11.33% in Q4 2025 and fell as low as 93.53% in Q1 2022.
• Historically, Return on Capital Employed has averaged 27.1% across 5 years, with a median of 29.85% in 2022.
• Across the five-year window, Return on Capital Employed tumbled 1110 bps in 2022 and soared 7326 bps in 2023, its largest moves.
• Year by year, Return on Capital Employed stood at 29.85% in 2022, then slipped by 12 bps to 33.4% in 2023, then retreated by 14 bps to 37.95% in 2024, then jumped by 130 bps to 11.33% in 2025, then sank by 76 bps to 2.7% in 2026.
• Per Business Quant data, the three most recent Return on Capital Employed figures were 2.7% in Q1 2026, 11.33% in Q4 2025, and 8.01% in Q3 2025.